198 related articles for article (PubMed ID: 11572863)
1. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease.
Chai Y; Wu L; Griffin JD; Paulson HL
J Biol Chem; 2001 Nov; 276(48):44889-97. PubMed ID: 11572863
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of polyglutamine proteins on nuclear organization and artificial reporter splicing.
Sun J; Xu H; Negi S; Subramony SH; Hebert MD
J Neurosci Res; 2007 Aug; 85(11):2306-17. PubMed ID: 17526020
[TBL] [Abstract][Full Text] [Related]
3. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
4. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death.
Huynh DP; Yang HT; Vakharia H; Nguyen D; Pulst SM
Hum Mol Genet; 2003 Jul; 12(13):1485-96. PubMed ID: 12812977
[TBL] [Abstract][Full Text] [Related]
5. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease.
Takahashi J; Tanaka J; Arai K; Funata N; Hattori T; Fukuda T; Fujigasaki H; Uchihara T
J Neuropathol Exp Neurol; 2001 Apr; 60(4):369-76. PubMed ID: 11305872
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation.
Krol HA; Krawczyk PM; Bosch KS; Aten JA; Hol EM; Reits EA
PLoS One; 2008 Jan; 3(1):e1503. PubMed ID: 18231590
[TBL] [Abstract][Full Text] [Related]
8. CREB-binding protein sequestration by expanded polyglutamine.
McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-1 fusion partners alter polyQ lethality and aggregation.
Rich T; Varadaraj A
PLoS One; 2007 Oct; 2(10):e1014. PubMed ID: 17925862
[TBL] [Abstract][Full Text] [Related]
10. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.
Perez MK; Paulson HL; Pittman RN
Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285
[TBL] [Abstract][Full Text] [Related]
11. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
12. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.
Uchihara T; Fujigasaki H; Koyano S; Nakamura A; Yagishita S; Iwabuchi K
Acta Neuropathol; 2001 Aug; 102(2):149-52. PubMed ID: 11563629
[TBL] [Abstract][Full Text] [Related]
13. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
14. PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.
Jia NL; Fei EK; Ying Z; Wang HF; Wang GH
Neurosci Bull; 2008 Aug; 24(4):201-8. PubMed ID: 18668148
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
Fu L; Gao YS; Sztul E
Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
[TBL] [Abstract][Full Text] [Related]
17. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
Stenoien DL; Mielke M; Mancini MA
Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
[TBL] [Abstract][Full Text] [Related]
18. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
19. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
20. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
